Titre : Benzocycloheptènes

Benzocycloheptènes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Neurofibroma
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzocycloheptènes : Questions médicales les plus fréquentes", "headline": "Benzocycloheptènes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzocycloheptènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-11", "dateModified": "2025-03-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzocycloheptènes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hydrocarbures aromatiques polycycliques", "url": "https://questionsmedicales.fr/mesh/D011084", "about": { "@type": "MedicalCondition", "name": "Hydrocarbures aromatiques polycycliques", "code": { "@type": "MedicalCode", "code": "D011084", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Dibenzocycloheptènes", "alternateName": "Dibenzocycloheptenes", "url": "https://questionsmedicales.fr/mesh/D003986", "about": { "@type": "MedicalCondition", "name": "Dibenzocycloheptènes", "code": { "@type": "MedicalCode", "code": "D003986", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Amitriptyline", "alternateName": "Amitriptyline", "url": "https://questionsmedicales.fr/mesh/D000639", "about": { "@type": "MedicalCondition", "name": "Amitriptyline", "code": { "@type": "MedicalCode", "code": "D000639", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.100" } } }, { "@type": "MedicalWebPage", "name": "Butaclamol", "alternateName": "Butaclamol", "url": "https://questionsmedicales.fr/mesh/D002069", "about": { "@type": "MedicalCondition", "name": "Butaclamol", "code": { "@type": "MedicalCode", "code": "D002069", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.230" } } }, { "@type": "MedicalWebPage", "name": "Cyproheptadine", "alternateName": "Cyproheptadine", "url": "https://questionsmedicales.fr/mesh/D003533", "about": { "@type": "MedicalCondition", "name": "Cyproheptadine", "code": { "@type": "MedicalCode", "code": "D003533", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.340" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Loratadine", "alternateName": "Loratadine", "url": "https://questionsmedicales.fr/mesh/D017336", "about": { "@type": "MedicalCondition", "name": "Loratadine", "code": { "@type": "MedicalCode", "code": "D017336", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.340.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Loratadine", "alternateName": "Loratadine", "url": "https://questionsmedicales.fr/mesh/D017336", "about": { "@type": "MedicalCondition", "name": "Loratadine", "code": { "@type": "MedicalCode", "code": "D017336", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.340.500" } } }, { "@type": "MedicalWebPage", "name": "Maléate de dizocilpine", "alternateName": "Dizocilpine Maleate", "url": "https://questionsmedicales.fr/mesh/D016291", "about": { "@type": "MedicalCondition", "name": "Maléate de dizocilpine", "code": { "@type": "MedicalCode", "code": "D016291", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.380" } } }, { "@type": "MedicalWebPage", "name": "Nortriptyline", "alternateName": "Nortriptyline", "url": "https://questionsmedicales.fr/mesh/D009661", "about": { "@type": "MedicalCondition", "name": "Nortriptyline", "code": { "@type": "MedicalCode", "code": "D009661", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.535" } } }, { "@type": "MedicalWebPage", "name": "Protriptyline", "alternateName": "Protriptyline", "url": "https://questionsmedicales.fr/mesh/D011530", "about": { "@type": "MedicalCondition", "name": "Protriptyline", "code": { "@type": "MedicalCode", "code": "D011530", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.650" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Benzocycloheptènes", "alternateName": "Benzocycloheptenes", "code": { "@type": "MedicalCode", "code": "D001567", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jiatian Li", "url": "https://questionsmedicales.fr/author/Jiatian%20Li", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } }, { "@type": "Person", "name": "Xiangwen Tan", "url": "https://questionsmedicales.fr/author/Xiangwen%20Tan", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } }, { "@type": "Person", "name": "Huanfeng Jiang", "url": "https://questionsmedicales.fr/author/Huanfeng%20Jiang", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } }, { "@type": "Person", "name": "Wanqing Wu", "url": "https://questionsmedicales.fr/author/Wanqing%20Wu", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.", "datePublished": "2024-05-29", "url": "https://questionsmedicales.fr/article/38811427", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s41687-024-00732-w" } }, { "@type": "ScholarlyArticle", "name": "RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.", "datePublished": "2023-05-27", "url": "https://questionsmedicales.fr/article/37245145", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jid.2023.01.043" } }, { "@type": "ScholarlyArticle", "name": "Beyond schwannomas and neurofibromas: a radiological and histopathological review of lesser-known benign lesions that arise in association with peripheral nerves.", "datePublished": "2022-10-25", "url": "https://questionsmedicales.fr/article/36280619", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00256-022-04207-1" } }, { "@type": "ScholarlyArticle", "name": "Letter to editor: Minimally invasive tubular removal of spinal schwannoma and neurofibroma - a case series of 49 patients and review of literature.", "datePublished": "2024-09-12", "url": "https://questionsmedicales.fr/article/39261325", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10143-024-02831-0" } }, { "@type": "ScholarlyArticle", "name": "Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.", "datePublished": "2022-07-31", "url": "https://questionsmedicales.fr/article/35987723", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.pathol.2022.05.012" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés polycycliques", "item": "https://questionsmedicales.fr/mesh/D011083" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures aromatiques polycycliques", "item": "https://questionsmedicales.fr/mesh/D011084" }, { "@type": "ListItem", "position": 4, "name": "Benzocycloheptènes", "item": "https://questionsmedicales.fr/mesh/D001567" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzocycloheptènes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzocycloheptènes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzocycloheptènes", "description": "Comment identifier les benzocycloheptènes ?\nQuels tests sont utilisés pour les benzocycloheptènes ?\nLes benzocycloheptènes sont-ils détectables dans le sang ?\nY a-t-il des marqueurs spécifiques pour ces composés ?\nPeut-on utiliser l'imagerie pour les benzocycloheptènes ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Neurofibroma&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzocycloheptènes", "description": "Quels sont les effets secondaires des benzocycloheptènes ?\nLes benzocycloheptènes causent-ils des douleurs ?\nY a-t-il des symptômes neurologiques associés ?\nPeut-on observer des symptômes cutanés ?\nLes benzocycloheptènes affectent-ils le système respiratoire ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Neurofibroma&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzocycloheptènes", "description": "Comment prévenir l'exposition aux benzocycloheptènes ?\nY a-t-il des formations pour manipuler ces composés ?\nQuels sont les risques en milieu industriel ?\nDes réglementations existent-elles pour leur usage ?\nComment évaluer les risques d'exposition ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Neurofibroma&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzocycloheptènes", "description": "Comment traiter une intoxication aux benzocycloheptènes ?\nY a-t-il des antidotes pour ces composés ?\nQuels médicaments peuvent aider en cas d'allergie ?\nLes benzocycloheptènes nécessitent-ils une hospitalisation ?\nComment gérer les effets à long terme ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Neurofibroma&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzocycloheptènes", "description": "Quelles complications peuvent survenir avec ces composés ?\nLes benzocycloheptènes peuvent-ils causer des cancers ?\nY a-t-il des effets sur la reproduction ?\nPeut-on développer des allergies à long terme ?\nLes benzocycloheptènes affectent-ils le système immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Neurofibroma&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzocycloheptènes", "description": "Qui est le plus à risque d'exposition ?\nL'âge influence-t-il la sensibilité ?\nY a-t-il des prédispositions génétiques ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'environnement de travail influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Neurofibroma&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les benzocycloheptènes ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par des techniques de spectroscopie et de chromatographie." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les benzocycloheptènes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de toxicité et d'efficacité sont réalisés en laboratoire." } }, { "@type": "Question", "name": "Les benzocycloheptènes sont-ils détectables dans le sang ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être détectés par des analyses spécifiques dans des échantillons biologiques." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour ces composés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs biologiques peuvent indiquer l'exposition à ces composés." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour les benzocycloheptènes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie moléculaire peut aider à visualiser leur distribution dans les tissus." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des benzocycloheptènes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent provoquer des nausées, des vertiges ou des réactions allergiques." } }, { "@type": "Question", "name": "Les benzocycloheptènes causent-ils des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs peuvent survenir en cas de toxicité ou d'allergie." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des maux de tête ou des troubles de la coordination peuvent apparaître." } }, { "@type": "Question", "name": "Peut-on observer des symptômes cutanés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées peuvent survenir en cas de réaction allergique." } }, { "@type": "Question", "name": "Les benzocycloheptènes affectent-ils le système respiratoire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition excessive peut entraîner des irritations respiratoires." } }, { "@type": "Question", "name": "Comment prévenir l'exposition aux benzocycloheptènes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire." } }, { "@type": "Question", "name": "Y a-t-il des formations pour manipuler ces composés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des formations spécifiques sont souvent requises pour les chercheurs." } }, { "@type": "Question", "name": "Quels sont les risques en milieu industriel ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs peuvent être exposés à des niveaux élevés sans protection adéquate." } }, { "@type": "Question", "name": "Des réglementations existent-elles pour leur usage ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des réglementations strictes encadrent leur utilisation en laboratoire et en industrie." } }, { "@type": "Question", "name": "Comment évaluer les risques d'exposition ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des évaluations de risque doivent être effectuées régulièrement dans les environnements de travail." } }, { "@type": "Question", "name": "Comment traiter une intoxication aux benzocycloheptènes ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'élimination de l'exposition et des soins symptomatiques." } }, { "@type": "Question", "name": "Y a-t-il des antidotes pour ces composés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzocycloheptènes." } }, { "@type": "Question", "name": "Quels médicaments peuvent aider en cas d'allergie ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des antihistaminiques peuvent être utilisés pour traiter les réactions allergiques." } }, { "@type": "Question", "name": "Les benzocycloheptènes nécessitent-ils une hospitalisation ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une hospitalisation peut être nécessaire en cas de symptômes graves." } }, { "@type": "Question", "name": "Comment gérer les effets à long terme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi médical régulier est recommandé pour surveiller les effets à long terme." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces composés ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des lésions organiques peuvent survenir en cas d'exposition prolongée." } }, { "@type": "Question", "name": "Les benzocycloheptènes peuvent-ils causer des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires." } }, { "@type": "Question", "name": "Y a-t-il des effets sur la reproduction ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des effets néfastes sur la reproduction ont été observés dans certaines études animales." } }, { "@type": "Question", "name": "Peut-on développer des allergies à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des sensibilisations peuvent se développer avec une exposition répétée." } }, { "@type": "Question", "name": "Les benzocycloheptènes affectent-ils le système immunitaire ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition prolongée peut altérer la fonction immunitaire, augmentant les infections." } }, { "@type": "Question", "name": "Qui est le plus à risque d'exposition ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs en laboratoire et en industrie chimique sont les plus exposés." } }, { "@type": "Question", "name": "L'âge influence-t-il la sensibilité ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes et les personnes âgées peuvent être plus sensibles aux effets toxiques." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines prédispositions génétiques peuvent augmenter la sensibilité aux toxines." } }, { "@type": "Question", "name": "Les antécédents médicaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies respiratoires augmentent le risque." } }, { "@type": "Question", "name": "L'environnement de travail influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un environnement de travail mal ventilé augmente le risque d'exposition." } } ] } ] }

Sources (195 au total)

Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.

Almost all patients with Neurofibromatosis type 1 (NF1) develop cutaneous neurofibroma (cNF), benign dermal tumours that have a large impact on the patient's Quality of Life (QoL). The French cNF-Skin... The questionnaire was translated using forward and backwards translation, and subsequently administered to a sample of 59 patients on two separate occasions. Feasibility was evaluated by the presence ... The Dutch cNF-Skindex demonstrated excellent feasibility and reliability (Cronbach's alpha 0.96, test-retest correlation coefficient 0.88). Convergent validity was confirmed for the EQ-5D-5L and relev... The Dutch cNF-Skindex displayed excellent psychometric properties, enabling use in the Netherlands....

Beyond schwannomas and neurofibromas: a radiological and histopathological review of lesser-known benign lesions that arise in association with peripheral nerves.

Peripheral nerve sheath tumors comprise a significant percentage of both benign and malignant soft tissue tumors. The vast majority of these lesions are schwannomas and neurofibromas, which most radio...

Letter to editor: Minimally invasive tubular removal of spinal schwannoma and neurofibroma - a case series of 49 patients and review of literature.

The article on "Minimally invasive tubular removal of spinal schwannoma and neurofibroma - a case series of 49 patients and review of the literature" by Dr Argiti et al. in Neurosurgical Review journa...

Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.

High expression of PRAME (PReferentially expressed Antigen in MElanoma) and p53 (a proposed marker of desmoplastic melanoma) and low expression of 5-hydroxymethylcytosine (5-hmC) have each been report...

Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.

Neurofibromatosis 1 (NF1) is a common autosomal dominant syndrome with complete penetrance and highly variable expressivity. The cutaneous neurofibroma (Cnf) and plexiform neurofibroma (Pnf), café-au-... A case-control study was conducted with 168 individuals, 84 with NF1 and 84 without NF1, paired by sex and age. Head circumference and anthropometric measurements, Snf quantification, evaluation of cl... Prevalence of macrocephaly was significantly higher in NF1 women. Height and weight were significantly lower in both males and females with NF1. HCHR was higher in the NF1 group than in the control gr... NF1 individuals have increased prevalence of macrocephaly, short stature, low BMI, and reduced abdominal fat. There is no relation between head circumference and anthropometric data with family histor...

Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.

Internal neurofibromas, including plexiform neurofibromas (PNF), can cause significant morbidity in patients with neurofibromatosis type 1 (NF1). PNF growth is most pronounced in children and young ad... In this prospective cohort study, internal neurofibromas were identified on coronal short TI inversion recovery sequences on baseline and follow-up whole-body MRIs (WBMRIs). Tumor growth and shrinkage... Of 106 patients with a baseline WBMRI obtained as part of a previous research study, 44 had a follow-up WBMRI. Three additional patients with WBMRIs acquired for clinical care were included, generatin... Internal neurofibroma growth behavior in older adults differs fundamentally from that in children and young adults, with most tumors, including DNL, demonstrating spontaneous shrinkage. Better growth ...

snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.

Neurofibromatosis Type 1 (NF1) is caused by loss of function variants in the NF1 gene. Most patients with NF1 develop skin lesions called cutaneous neurofibromas (cNFs). Currently the only approved th...

Giant cell granuloma and neurofibroma in the mandible of a patient with neurofibromatosis type 1: a long-term follow-up case report with radiological and surgical aspects and a review of the literature.

Magnetic resonance imaging (MRI) of the brain is frequently performed on patients with neurofibromatosis type 1 (NF1), to detect and follow-up intracranial findings. In addition, NF1-related pathologi... We report on the 3-year management with clinical and radiological follow-ups of a central giant cell granuloma and a neurofibroma in the mandible of a patient with NF1 who underwent examinations with ... NF1-related jaw pathologies may be detected in the early stages if the depicted parts of the jaws are included in the assessment of the imaging of NF1 patients with intracranial findings. This could i...